ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

OUR STORY

Our Vision

2022-11-30 08:00:00

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about us:

Ascelia Pharma FDA and SPARKLE Update December 2022 (PDF)

Webcast Pressrelease December 2022

Quarterly Report Q3-2022

Q3-2022 Investor Conference Call

Ascelia Pharma Company Presentation December 2022

About us

New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients

2022.12.06

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that new data show that the pivotal Phase […]

QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

2022-11-04 08:00:00

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2022(January – September 2022), which is now available on the company’s website: https://www.ascelia.com/ir …

New market research shows strong support for Orviglance

2022.03.29

New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function.

INVESTOR

Shortcut to our latest Financial Reports

IR & Media

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

Our Vision

New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients

QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

New market research shows strong support for Orviglance

Upcoming Events

Full-Year report 2022

Latest News

71 patients have completed the SPARKLE study

65 patients have completed the SPARKLE study

New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients

Presentations & Articles

ABGSC Investor Day

HC Andersen – Oncology Seminar

Erik Penser Bank – Company Day

Shortcut to our latest Financial Reports

About us

Meet us

Our values

About us

Pipeline

IR & Media

Contact us

Follow us

ADVANCINGORPHAN ONCOLOGY

Our Vision

New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients

QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

New market research shows strong support for Orviglance

Upcoming Events

Full-Year report 2022

Latest News

71 patients have completed the SPARKLE study

65 patients have completed the SPARKLE study

New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients

Presentations & Articles

ABGSC Investor Day

HC Andersen – Oncology Seminar

Erik Penser Bank – Company Day

Shortcut to our latest Financial Reports

About us

Meet us

Our values

ADVANCING
ORPHAN ONCOLOGY